Announced Wed, 19 Aug · 17:38 IST
Sandu Pharma files 41st Annual Report, 10% dividend, new auditor proposed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹38.00
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-0.1+0.0-2.6-3.4-5.3-0.7-0.3-1.3——
Up moveDown movePending
AI summary
Sandu Pharmaceuticals filed its 41st Annual Report for FY26. Revenue stood at Rs 6,993.45 lakhs with net profit up 23.187%. Board proposes Rs 1 per share dividend (10%). AGM on 11 September 2026 via video conferencing. Seeks shareholder approval for new statutory auditor M/s Dave and Dave for 5 years, material related party transactions with Sandu Brothers up to Rs 100 crore, redesignation of Balram Viswanathan as Chairman and MD, and appointment of Dr Neeti Kapre as Independent Director.
Likely market impact
PAT up about 23%, 10% dividend proposed. Key agenda items include new auditor and Rs 100 crore RPT limit with group firm.